Teladoc Health, Inc. (NYSE:TDOC – Get Rating) insider Adam C. Vandervoort sold 3,877 shares of the stock in a transaction that occurred on Thursday, March 2nd. The shares were sold at an average price of $25.36, for a total transaction of $98,320.72. Following the sale, the insider now directly owns 15,629 shares of the company’s stock, valued at $396,351.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Teladoc Health Price Performance
NYSE TDOC opened at $26.88 on Monday. The company has a quick ratio of 3.15, a current ratio of 3.29 and a debt-to-equity ratio of 0.67. The stock has a market capitalization of $4.37 billion, a PE ratio of -0.32 and a beta of 1.08. The company has a 50 day moving average price of $27.22 and a two-hundred day moving average price of $27.99. Teladoc Health, Inc. has a 12-month low of $21.60 and a 12-month high of $77.50.
Teladoc Health (NYSE:TDOC – Get Rating) last posted its earnings results on Wednesday, February 22nd. The health services provider reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.04. The firm had revenue of $637.71 million during the quarter, compared to analysts’ expectations of $633.71 million. Teladoc Health had a negative net margin of 567.53% and a negative return on equity of 4.35%. As a group, equities analysts predict that Teladoc Health, Inc. will post -1.41 earnings per share for the current fiscal year.
Institutional Trading of Teladoc Health
Analysts Set New Price Targets
Several research analysts have issued reports on the company. Oppenheimer dropped their price target on Teladoc Health from $37.00 to $35.00 and set an “outperform” rating on the stock in a report on Thursday, February 23rd. Barclays cut their target price on Teladoc Health from $32.00 to $28.00 and set an “equal weight” rating on the stock in a research report on Wednesday, January 18th. Citigroup dropped their price target on Teladoc Health from $33.00 to $30.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 28th. StockNews.com raised shares of Teladoc Health to a “sell” rating in a research note on Friday, February 24th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $35.00 target price on shares of Teladoc Health in a research report on Thursday, February 23rd. One investment analyst has rated the stock with a sell rating, nineteen have given a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $36.96.
About Teladoc Health
Teladoc Health, Inc engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. Its portfolio of services and solutions covers medical subspecialties from non-urgent, episodic needs like flu and upper respiratory infections, to chronic, complicated medical conditions like cancer and congestive heart failure.
Further Reading
- Get a free copy of the StockNews.com research report on Teladoc Health (TDOC)
- MarketBeat Week in Review – 2/27 – 3/3
- The 3 Most Upgraded Stocks Are Reversing
- How to Find Blue Chip Dividend Stocks
- Zscaler, Inc Plummets, Is It Time To Buy The Dip?
- What is a Good Dividend Yield? How to Decide
Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.